Sowell Financial Services LLC Neurocrine Biosciences Inc Transaction History

Sowell Financial Services LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$130.86 - $143.19 $261 - $286	-2 Reduced 0.02%	10,914 $1.5 Million
Q1 2024 May 03, 2024	BUY	$130.4 - $143.74 $1.42 Million - $1.57 Million	10,916 New	10,916 $1.51 Million
Q2 2021 Aug 05, 2021	SELL	$89.43 - $102.27 $138,974 - $158,927	-1,554 Closed	0 $0
Q1 2021 May 07, 2021	SELL	$87.57 - $119.4 $8,669 - $11,820	-99 Reduced 5.99%	1,554 $139,000
Q4 2020 Jan 13, 2021	BUY	$86.91 - $108.33 $15,817 - $19,716	182 Added 12.37%	1,653 $158,000
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $40,291 - $56,627	-419 Reduced 22.17%	1,471 $141,000
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $86,281 - $132,185	1,014 Added 115.75%	1,890 $231,000
Q1 2020 May 12, 2020	BUY	$75.11 - $113.76 $4,731 - $7,166	63 Added 7.75%	876 $76,000
Q4 2019 Feb 07, 2020	BUY	$86.8 - $118.57 $57,201 - $78,137	659 Added 427.92%	813 $87,000
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $12,908 - $15,631	154 New	154 $14,000

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Sowell Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on Sowell Financial Services LLC with notifications on news.